Standard

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. / Oppedijk, Vera; van der Gaast, Ate; van Lanschot, Jan J. B. et al.

In: Journal of clinical oncology, Vol. 32, No. 5, 2014, p. 385-391.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Oppedijk, V, van der Gaast, A, van Lanschot, JJB, van Hagen, P, van Os, R, van Rij, CM, van der Sangen, MJ, Beukema, JC, Rütten, H, Spruit, PH, Reinders, JG, Richel, DJ, van Berge Henegouwen, MI & Hulshof, MCCM 2014, 'Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials', Journal of clinical oncology, vol. 32, no. 5, pp. 385-391. https://doi.org/10.1200/JCO.2013.51.2186

APA

Oppedijk, V., van der Gaast, A., van Lanschot, J. J. B., van Hagen, P., van Os, R., van Rij, C. M., van der Sangen, M. J., Beukema, J. C., Rütten, H., Spruit, P. H., Reinders, J. G., Richel, D. J., van Berge Henegouwen, M. I., & Hulshof, M. C. C. M. (2014). Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. Journal of clinical oncology, 32(5), 385-391. https://doi.org/10.1200/JCO.2013.51.2186

Vancouver

Oppedijk V, van der Gaast A, van Lanschot JJB, van Hagen P, van Os R, van Rij CM et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. Journal of clinical oncology. 2014;32(5):385-391. doi: 10.1200/JCO.2013.51.2186

Author

Oppedijk, Vera ; van der Gaast, Ate ; van Lanschot, Jan J. B. et al. / Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. In: Journal of clinical oncology. 2014 ; Vol. 32, No. 5. pp. 385-391.

BibTeX

@article{c5c52059a09e4b6aac7859f1bdec53ce,
title = "Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials",
abstract = "To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone. Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin. Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75%). Of the 374 patients who underwent resection, 86% were allocated to surgery and 92% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58% versus 35% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35% v 29%; P = .025). LRR occurred in 5% within the target volume, in 2% in the margins, and in 6% outside the radiation target volume. In 1%, the exact site in relation to the target volume was unclear. Only 1% had an isolated infield recurrence after CRT plus surgery. Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5%, mostly combined with outfield failures",
author = "Vera Oppedijk and {van der Gaast}, Ate and {van Lanschot}, {Jan J. B.} and {van Hagen}, Pieter and {van Os}, Rob and {van Rij}, {Caroline M.} and {van der Sangen}, {Maurice J.} and Beukema, {Jannet C.} and Heidi R{\"u}tten and Spruit, {Patty H.} and Reinders, {Janny G.} and Richel, {Dick J.} and {van Berge Henegouwen}, {Mark I.} and Hulshof, {Maarten C. C. M.}",
year = "2014",
doi = "10.1200/JCO.2013.51.2186",
language = "English",
volume = "32",
pages = "385--391",
journal = "Journal of clinical oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

RIS

TY - JOUR

T1 - Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials

AU - Oppedijk, Vera

AU - van der Gaast, Ate

AU - van Lanschot, Jan J. B.

AU - van Hagen, Pieter

AU - van Os, Rob

AU - van Rij, Caroline M.

AU - van der Sangen, Maurice J.

AU - Beukema, Jannet C.

AU - Rütten, Heidi

AU - Spruit, Patty H.

AU - Reinders, Janny G.

AU - Richel, Dick J.

AU - van Berge Henegouwen, Mark I.

AU - Hulshof, Maarten C. C. M.

PY - 2014

Y1 - 2014

N2 - To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone. Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin. Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75%). Of the 374 patients who underwent resection, 86% were allocated to surgery and 92% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58% versus 35% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35% v 29%; P = .025). LRR occurred in 5% within the target volume, in 2% in the margins, and in 6% outside the radiation target volume. In 1%, the exact site in relation to the target volume was unclear. Only 1% had an isolated infield recurrence after CRT plus surgery. Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5%, mostly combined with outfield failures

AB - To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone. Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin. Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75%). Of the 374 patients who underwent resection, 86% were allocated to surgery and 92% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58% versus 35% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34% to 14% (P < .001) and peritoneal carcinomatosis from 14% to 4% (P < .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35% v 29%; P = .025). LRR occurred in 5% within the target volume, in 2% in the margins, and in 6% outside the radiation target volume. In 1%, the exact site in relation to the target volume was unclear. Only 1% had an isolated infield recurrence after CRT plus surgery. Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5%, mostly combined with outfield failures

U2 - 10.1200/JCO.2013.51.2186

DO - 10.1200/JCO.2013.51.2186

M3 - Article

C2 - 24419108

VL - 32

SP - 385

EP - 391

JO - Journal of clinical oncology

JF - Journal of clinical oncology

SN - 0732-183X

IS - 5

ER -

ID: 2301567